Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
18 authors.
Marcelo AntoniniDepartment of Breast Surgery, Hospital do Servidor Público Estadual Francisco Morato de Oliveira, Sao Paulo 04039-000, SP, Brazil.ORCID 0000-0002-1996-7428
Raissa Barros VasconcelosDepartment of Breast Surgery, Hospital do Servidor Público Estadual Francisco Morato de Oliveira, Sao Paulo 04039-000, SP, Brazil.ORCID 0009-0001-9053-9784
André MattarBBREAST-Brazilian Breast Association Team, Sao Paulo 01258-011, SP, Brazil.ORCID 0000-0001-5973-623X
Mariana Pollone MedeirosDepartment of Breast Surgery, Hospital do Servidor Público Estadual Francisco Morato de Oliveira, Sao Paulo 04039-000, SP, Brazil.
Marina Diógenes TeixeiraDepartment of Breast Surgery, Centro de Referência da Saúde da Mulher-Hospital da Mulher, Sao Paulo 01206-001, SP, Brazil.ORCID 0009-0001-7516-0215
Andressa Gonçalves AmorimDepartment of Breast Surgery, Centro de Referência da Saúde da Mulher-Hospital da Mulher, Sao Paulo 01206-001, SP, Brazil.
Odair FerraroDepartment of Breast Surgery, Hospital do Servidor Público Estadual Francisco Morato de Oliveira, Sao Paulo 04039-000, SP, Brazil.
Larissa Chrispim de OliveiraDepartment of Breast Surgery, Centro de Referência da Saúde da Mulher-Hospital da Mulher, Sao Paulo 01206-001, SP, Brazil.
Marcellus do Nascimento Moreira RamosDepartment of Breast Surgery, Centro de Referência da Saúde da Mulher-Hospital da Mulher, Sao Paulo 01206-001, SP, Brazil.
Francisco Pimentel CavalcanteDepartment of Breast Surgery, Hospital Geral de Fortaleza, Fortaleza 60150-160, CE, Brazil.ORCID 0000-0002-7156-2890
Felipe ZerwesDepartment of Breast Surgery, Medical School of the Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre 90619-900, RS, Brazil.ORCID 0000-0002-1643-727X
Marcelo MadeiraDepartment of Breast Surgery, Faculdade Israelita de Ciências da Saúde Albert Einstein, Sao Paulo 05653-000, SP, Brazil.ORCID 0000-0001-9429-3067
Eduardo de Camargo MillenDepartment of Breast Surgery, Americas Oncologia, Rio de Janeiro 22793-080, RJ, Brazil.ORCID 0000-0002-2113-6324
Antonio Luiz FrassonDepartment of Breast Surgery, Hospital Albert Einstein, Sao Paulo 05651-901, SP, Brazil.
Fabricio Palermo BrenelliDepartment of Breast Surgery, Universidade Estadual de Campinas (UNICAMP), Campinas 13082-859, SP, Brazil.
Gil FacinaDepartment of Gynecology, Universidade Federal de Sao Paulo, Sao Paulo 04023-062, SP, Brazil.ORCID 0000-0003-1418-0295
Henrique Lima CoutoDepartment of Breast Surgery, REDIMAMA-REDIMASTO, Belo Horizonte 30110-022, MG, Brazil.ORCID 0000-0002-3789-4461
Luiz Henrique GebrimDepartment of Breast Surgery, Hospital Beneficiencia Portuguesa, Sao Paulo 01438-000, SP, Brazil.ORCID 0000-0001-9941-9191
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
backgroundDuctal carcinoma
methodsThis retrospective, cross-sectional study reviewed medical records of 145 patients treated for DCIS at HSPE between January 1996 and June 2022, with a mean follow-up of 60.3 months.
resultsBased on VNPI, 38.8% were low risk, 53.2% intermediate risk, and 7.8% high risk. NCCN guidelines classified only 12.9% as low risk and 87.1% as high risk. Treatment included breast-conserving surgery (BCS) with radiotherapy (43.1%), BCS alone (38.8%), and mastectomy (18.1%). There were 18 recurrences (15.5%): 5.2% as DCIS and 10.3% as invasive cancer. Of these recurrences, 5.6% occurred in patients who, according to NCCN, would have received BCS with radiotherapy or mastectomy.
conclusionBy integrating the VNPI with NCCN treatment guidelines, the NCCN's recommendations could potentially reduce local recurrence rates by 5.6%. However, further studies are necessary to evaluate the long-term impact of these guidelines on overall survival outcomes.
Indexed as
DCIS treatmentductal carcinoma in situinvasive breast cancerNational Comprehensive Cancer NetworkVan Nuys Prognostic Index
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Comparative Analyses of Van Nuys Prognostic Index and NCCN Guidelines in Ductal Carcinoma · full record | Socratic